| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Record information and status
Record ID
Date of creation
2014-01-22 20:12 UTC (gutemberg.sousa@mctic.gov.br)
Date of publication
2014-01-27 15:01 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Transformation event
Dr Alexis Henry Gaetan Goux
President of CIBio
Ceva Saúde Animal Ltda (CEVA)
Rua Manuel Joaquim Filho, 303 Pulínia - SP
Paulínia, São Paulo
Brazil, 13140-000
VECTORMUNE® FP LT is a genetically engineered, live Fowl Pox virus vaccine for use in chickens. The Fowl Pox virus has been genetically modified to express key protective Laryngotracheitis (LT) virus antigens.
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Fowlpox virus - FOWPV
Related LMOs
Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the transformation process
Techniques used for the modification
  • Homologous Recombination
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
UL32 gene - Gallid alphaherpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Glycoprotein B gene - Gallid alphaherpesvirus 1 - ILTV
Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Notes regarding the genetic elements introduced or modified in this LMO
Two genes originating from ILTV, namely UL32 and gB, were introduced into a FPV vector. The genes were ligated into a pUC18 transformation vector in addition to a lacZ marker gene from E. coli, using two synthetic promoters and an FPV homologous recombination site.

The vector was constructed by cloning a 3 kb fragment of FPV genomic DNA into the pUC18 vector. An internal fragment of 175bp was removed and replaced by a construct containing the UL32 coding sequenece with a synthetic PS promoter, followed by a lacZ gene directed by the synthetic promoter P17. This was followed by the coding sequence of the gB gene which was also directed by the synthetic promoter PS.

The synthetic promoters PS and P17 emulate the consensus early/late promoter and the early poxvirus promoter, respectively. Genes gB and UL32 code for the ILTV antigens, while the gene lacZ operates as a reporter gene to facilitate recombinant virus selection.

This construct and the the parental FPV strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.

Homologous recombination and integration of the genetic construct was confirmed by Southern blot using probes that hybridized in both sides of the insertion site. DNA sequencing was also conducted. Expression of genes UL32 and gB was confirmed by Western blot.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine
Additional Information
Other relevant website address or attached documents

Records referencing this document (3)
3record(s) found
Country's Decision or any other Communication1 record
Modified Organism1 record
Risk Assessment1 record